Introduction
============

Steroid-sparing immunosupressants such as azathioprine (AZA) for the long-term course of myasthenia gravis (MG) are the preferred first-line treatment for generalized and severe ocular AchR-ab positive MG. However, 10-20% of MG patients treated with AZA do not respond sufficiently to AZA and side effects occur frequently (nausea, elevated liver enzymes, leuco- or thrombocytopenia).

Methods
=======

In the present prospective open-label study we replaced AZA by MMF in eleven patients with AChR-ab positive MG and analysed the effect and safety of MMF for a mean duration of 16.9 months ± 11.1 (6-46). Four patients with pure ocular and seven patients with generalized MG were included. AChR-ab titer, QMGS, MGFA postintervention status, and concomitant drugs were assessed before the beginning and during MMF treatment (Table [1](#T1){ref-type="table"}).

###### 

AChR-ab titer, quantitative MG score, MGFA postintervention status, and concomitant drugs were assessed before and after the beginning with MMF treatment in 11 patients with AChR-ab positive MG.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  nr./sex age   MGFA score   medication before MM treatment (mg)   reason for drug exchange   MMF duration (months)   Dose     serum level (Qg/ml)   concomitant treatment (mg)   MGFA postintervention status during MMF   change in status unchanged   QMGS            AChR-ab (nmol/l)   
  ------------- ------------ ------------------------------------- -------------------------- ----------------------- -------- --------------------- ---------------------------- ----------------------------------------- ---------------------------- ------- ------- ------------------ ------
  1\. m/67      I            PR 20\                                gGT increase (15-fold)     46                      2.0 g    2.26                  none                         complete pharmacologic remission                                       0/24    0/24    21                 17
                             AZA 150\                                                                                                                                                                                                                                                       
                             CH 360                                                                                                                                                                                                                                                         

  2\. m/52      I            PR 40\                                gGT increase (13-fold)     16                      2.0 g    2.15                  none                         minimal manifestations (mild ptosis)      unchanged                    3/24    3/24    3.6                10.4
                             AZA 150\                                                                                                                                                                                                                                                       
                             CH 240                                                                                                                                                                                                                                                         

  3.m/59        I            PR 20\                                gGT increase (5-fold)\     7                       2.0 g    2.43                  PR (7.5)                     severe right ptosis CH (480)              unchanged                    3/24    3/24    5.0                2.3
                             CH 330\                               drug resistancy                                                                                                                                                                                                          
                             AZA 150                                                                                                                                                                                                                                                        

                                                                                              36                      1.5 g    (GI-problems)         CH (20) IVIG10g/month        minimal manifestation mild ptosis         improvement                          1/24                       2.9

  4.f/33        I            PR 5\                                 nausea, vomiting           20                      2.0 g    2.97                  CH (180)                     incomplete pharmacol. Remission\          exacerbation                 1/24    5/24    0.21               0.44
                             CH 270\                                                                                                                                              after 20 mo generalization                                                                                
                             AZA 150                                                                                                                                                                                                                                                        

  5.m/77        IIa          PR 20\                                gGT increase\              20                      2.0 g\   n.a.\                 none                         pharmacologic remission                   unchanged                    0/24    0/24    1.6                6.7
                             AZA 150(13-fold)\                     pancyopenia                                        1.0 g    (flatulence)                                                                                                                                                 
                             CH 240                                                                                                                                                                                                                                                         

  6.f/64        IIa          PR 20\                                exacerbation               36                      2.0 g\   2.18                  CH (150)                     complete pharmacologic remission          improvement                  7/24    3/24    31                 39
                             AZA 200\                                                                                 2.5 g                                                                                                                                                                 
                             CH 240                                                                                                                                                                                                                                                         

  7.f/20        IIb          CH120\                                edema\                     20                      1.5 g    0.72                  CH (240)                     Complete pharmacol. remission             improvement                  6/24    4/24    43                 22
                             AZA 50                                (hand, feet)                                                                                                                                                                                                             

  8.f/43        IIIa         PR 25\                                lymphopenia                21                      1.5 g    1.90                  CH (240)                     Complete pharmacol. remission             improvement                  4/24    0/24    44                 34
                             CH 240\                                                                                                                                                                                                                                                        
                             AZA 150                                                                                                                                                                                                                                                        

  9.m/64        IIIa         PR\                                   amylase/8\                 2.0 g                   n.a.                           CH (345)                     therapyresistancy                         unchanged                    11/24   11/24   17                 21
                             CH\                                   lipase increase\                                                                                                                                                                                                         
                             AZA\                                  nausea, vomiting                                                                                                                                                                                                         
                             MTX                                                                                                                                                                                                                                                            

  10.f/33       IIIb         CH 330\                               recurrent 14\              1.0 g                   0.50\                          CH (270)                     incomplete pharmacol. remission\          improvement                  5/24    1/24    7.5                11.5
                             AZA 50                                pancytopenia\                                      0.5 g                                                       remission leucopenia                                                                                      
                                                                   persistent sympt.                                                                                                                                                                                                        

  11.m/59       V            PR 40\                                persistant sympt.          26                      2.0 g    3.05                  PR (7.5)\                    incomplete pharmacol. remission           improvement                  11/24   4/24    200                24
                             CH 540\                                                                                                                 CH (480)                                                                                                                               
                             AZA 150                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AchR-ab - acetylcholine receptor antibody, AZA - azathioprine, CH - choline esterase inhibitor, IVIG - intravenous immunoglobulins, MGFA - myasthenia gravis foundation association, MMF - mycophenolate mofetil, PR - prednisolone, QMGS, quantitative myasthenia gravis score for disease severity

^1^i.e. at the end of the observation period

Results
=======

The reasons for the exchange from AZA to MMF were gastrointestinal (liver enzyme increase n = 4, nausea/vomiting n = 2, increase of pancreatic enzymes n = 1) and haematological adverse effects (leuco- or pancytopenia n = 3), peripheral edema (n = 1), unresponsiveness to AZA (n = 3). According to the QMGS treatment resulted in complete (pat. 8) and incomplete (pat.6, 7, 10, 11) pharmacological remission, three patients remained in complete pharmacological remission (pat. 1, 5) or with minimal manifestation (pat. 2). Clinical improvement was seen after a period of 2-9 months. In two patients clinical improvement along with decreasing AChR-ab occurred after more than six months on MMF (pat. 7, 11). Patient 3 with disabling unilateral ptosis was refractory despite a combined therapy of prednisolone, high dose pyridostigmine, and MMF. Symptoms improved during a concomitant therapy of intravenous immunoglobins. Patient 4 showed signs of generalization (head lifting weakness) after 20 months on MMF. Patient 2 with mild unilateral ptosis discontinued MMF after sixteen months due to its fear of side effects. Concomitant medication (prednisolone, pyridostigmine) could be discontinued in 4 patients (pat. 1, 2, 5, 7) and reduced in 5 patients (pat. 4, 6, 8, 10, 11). Laboratory parameters which had led to the change from AZA to MMF normalized in all patients affected (n = 8) except pat. 9. In the latter patient MMF treatment had to be discontinued due to persistent increase of pancreatic enzymes and recurrent gastrointestinal problems. One patient was diagnosed with bronchial carcinoma after 10 months of MMF treatment (pat. 5). The daily MMF dosage ranged from 0.5 to 2.5 g and had to be reduced in three patients due to gastrointestinal problems (pat. 3), and persistent leucopenia (pat. 10).

Dicussion
=========

Anecdotic reports, uncontrolled open label and retro spective studies with MMF had shown clinical improvement and steroid dose reduction in patients with severe refractory MG \[[@B2],[@B4]\]. The time to improvement in that trials was highly variable and ranged from 2 weeks to 12 months \[[@B6],[@B7]\]. A small double-blind, placebo-controlled pilot trial of MMF with concomitant prednisolon and/or cyclosporine A medication in MG showed a significant improvement of MMF compared to placebo \[[@B3]\]. However, two recent randomized, double blind, placebo-controlled studies with larger cohorts failed to show a benefit for MMF in generalized MG using quantiative MG scores during a treatment period of 12 and 36 weeks, respectively \[[@B5],[@B6]\]. It is unclear whether this was due to the short duration of the follow-up period, the effect of the add-on steroid therapy, or the insufficient effect of MMF in MG itself. Consistent with our study side effects of MMF are often transitory and mild, including mostly gastrointestinal symptoms as nausea and diarrhoea or headache \[[@B4],[@B5]\]. However, severe side effects as an increased risk of lymphoproliferative disorders \[[@B7]\] and severe skin reactions might also be associated with MMF therapy. It remains open whether the bronchial cancer diagnosed in one of our patients was related to MMF.

The present study shows that MMF led to the reduction of concomitant medication and of AZA induced side effects in the majority of patients.
